US equities
|
MU
$1,097.39
▲+0.00%
NVDA
$230.86
▲+0.00%
SNDK
$1,787.69
▲+0.00%
STX
$945.57
▲+0.00%
WDC
$462.56
▲+0.00%
NKE
$35.15
▲+0.00%
MSTR
$160.50
▲+0.00%
AMD
$615.73
▲+0.00%
MU
$1,097.39
▲+0.00%
NVDA
$230.86
▲+0.00%
SNDK
$1,787.69
▲+0.00%
STX
$945.57
▲+0.00%
WDC
$462.56
▲+0.00%
NKE
$35.15
▲+0.00%
MSTR
$160.50
▲+0.00%
AMD
$615.73
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
(OP:
SDZNY
)
82.58
UNCHANGED
Delayed Quote
Updated: 3:58 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SDZNY
< Previous
1
2
Next >
Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive
March 03, 2026
As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...
Via
Finterra
Topics
Economy
Initial Public Offering
Retirement
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
January 23, 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...
Via
MarketMinute
Topics
Artificial Intelligence
Bankruptcy
Economy
Sandoz launches affordable iron sucrose injection for treatment of iron deficiency anemia in patients with chronic kidney disease in US
September 24, 2025
From
Sandoz
Via
Business Wire
Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations
August 12, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
August 07, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
July 30, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
July 01, 2025
From
Sandoz Group
Via
GlobeNewswire
Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor
↗
June 16, 2025
A simple oversight could end up costing Danish pharma giant Novo Nordisk A/S (NYSE: NVO) billions in potential losses on its blockbuster weight-loss and diabetes drug, Ozempic.
Via
Benzinga
Topics
Intellectual Property
Life Sciences Investor Forum: Now Available for Online Viewing
June 13, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
June 02, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
May 21, 2025
From
Sandoz Group
Via
GlobeNewswire
Life Sciences Investor Forum Agenda Announced for June 11th-12th
June 10, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
April 30, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
April 29, 2025
From
Sandoz Group
Via
GlobeNewswire
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
April 15, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
↗
April 14, 2025
Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market.
Via
Benzinga
Topics
Intellectual Property
Lawsuit
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
April 14, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
March 31, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports strong FY 2024 results and Q4 2024 sales
March 05, 2025
From
Sandoz Group
Via
GlobeNewswire
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
↗
February 24, 2025
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...
Via
Benzinga
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
February 24, 2025
From
Sandoz Group
Via
GlobeNewswire
Francisco Ballester to retire; Peter Stenico appointed President Region International
February 03, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025
From
Sandoz Group
Via
GlobeNewswire
Sandoz takes further steps to resolve legacy US Generic Drug Antitrust Class Action Litigation
December 17, 2024
From
Sandoz Group
Via
GlobeNewswire
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
↗
December 03, 2024
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.
Via
Benzinga
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
November 15, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz reports third-quarter and nine-month 2024 sales
October 30, 2024
From
Sandoz Group
Via
GlobeNewswire
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
October 11, 2024
From
Sandoz Group
Via
GlobeNewswire
Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines
October 02, 2024
Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines
Via
News Direct
< Previous
1
2
Next >
